Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on May 15, 2023 2:41pm
132 Views
Post# 35448774

RE:RE:RE:RE:RE:RE:RE:RE:RE:AGM was horrible

RE:RE:RE:RE:RE:RE:RE:RE:RE:AGM was horribleOn NASH, they took something that was not even thought to have a chance and advanced it rather amazingly to the rpecipice of being real. I doubt it will ever get there at this point but THTX leadership deserves kudos for taking something that was nothing as far as they have. They came close and I suppose there is still a very, very long shot it could become something in NASH. But I am not counting on it.
Joemare wrote: Honestly, if these many fails had happened when they were at Pfizer, Pfizer would have kicked their butts out in a flash. They got too many passes.  The issue is trust. Trust to deliver.
It's all about onco and NASH. NASH, they failed to move the needle. 


<< Previous
Bullboard Posts
Next >>